Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Understanding communication and information processing in nervous systems is a central
goal of neuroscience. Over the past two decades, advances in connectomics and network …

Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Aggregation of specific proteins are histopathological hallmarks of several
neurodegenerative diseases, such as, Amyloid β (Aβ) plaques and tau neurofibrillary …

Tau (MAPT) drives neuronal dysfunction in Alzheimer disease (AD) and other tauopathies.
To dissect the underlying mechanisms, we combined an engineered ascorbic acid …

Gene expression fundamentally shapes the structural and functional architecture of the
human brain. Open-access transcriptomic datasets like the Allen Human Brain Atlas provide …

Tau aggregation in neurofibrillary tangles (NFTs) is closely associated with
neurodegeneration and cognitive decline in Alzheimer's disease (AD). However, the …

The pathology of Alzheimer disease (AD) damages structural and functional brain networks,
resulting in cognitive impairment. The results of recent connectomics studies have now …